MissionIRNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Partners with Leading Mechanical, Plant Engineering Firm

 Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is partnering with Dürr, one of the world’s leading mechanical and plant engineering firms. Durr brings extensive expertise in automation and digitalization to the partnership, which is designed to focus on MULN’s EV manufacturing footprint. According to the agreement, Dürr, which has extensive expertise in automation and digitalization, will support Mullen’s Advanced Manufacturing and Engineering Center (“AMEC”) with full integration for vehicle assembly and complete paint shop technologies; the engineering center is located in Tunica, Mississippi. “Dürr is a leading international manufacturing systems and technology provider for the automotive industry,” said Mullen Automotive CEO and chair David Michery in the press release. “Our Tunica facility will be a leading example of manufacturing automation. Our goal is to have the best and most efficient manufacturing footprint in the U.S., and Dürr is a key partner in achieving this effort.”

To view the full press release, visit https://ibn.fm/Mbln2  

About Mullen

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment

 InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until their successors are elected or appointed. The company also noted that all of the matters outlined for consideration and approval in InMed’s notice of meeting and management information circular were approved. In addition, the company announced that an article discussing cannabinol (“CBN”) as a potential treatment option for glaucoma has been published in a peer-reviewed journal. The article, titled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma,” was published in the “Biochimica et Biophysical Acta” journal. The article concludes that, first, CBN may promote neuroprotection of cells in the retina that are responsible for vision, and second, the substance may normalize intraocular pressure by attenuating changes in the extracellular matrix proteins. “Having this research peer-reviewed and published in such a reputable journal is a significant milestone for InMed’s glaucoma development program,” said InMed scientific advisor Dr. Mauro Maccarrone in the press release. “This provides important external validation for the scientific community as the program advances towards human studies. We believe InMed’s INM-088 program has significant implications for neuroprotection within the glaucoma space and may lead to a potential new treatment for millions of people suffering from this condition worldwide.”

To view the full press releases, visit https://ibn.fm/gf6eQ and https://ibn.fm/SgLbL

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)

 Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced its entry into an advertising and media agreement for media buys and digital marketing with SRAX (NASDAQ: SRAX). Under the agreement, SRAX will act as the agent for Lexaria and will engage and manage media companies to create advertising materials and distribute them on internet platforms as well as manage the flow of such media distributions. SRAX will employ leading-edge analytical algorithms in order to maximize engagement. “Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long media outreach campaign,” said Chris Bunka, CEO of Lexaria Bioscience. “Lexaria has made tremendous progress during 2021 and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors.”

To view the full press release, visit https://ibn.fm/52b6b

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension

 

• Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure)
• The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
• Arterial stiffness is a noted indicator of diseases such as heart, kidney and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity
• HYPER-H21-2 results evidence DehydraTECH-CBD reduces arterial stiffness

Lexaria Bioscience (NASDAQ: LEXX), an innovator in how drugs are utilized by the human body, is reporting newly found benefits from cannabidiol (“CBD”) enhanced by Lexaria’s patented DehydraTECH(TM) technology. 

The company’s Dec. 8 news release notes that DehydraTECH-formulated CBD was found to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) patients volunteering in Lexaria’s HYPER-H21-2 human clinical study (https://ibn.fm/MJ0Xc). The company believes the findings may have a potential impact on efforts to treat not only high blood pressure, but other cardiovascular diseases and other ailments in which blood vessel stiffness is believed to play a significant role. 

“Reducing arterial stiffness in Lexaria’s recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” Lexaria President John Docherty stated in the news release. “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”

Lexaria’s examination of DehydraTECH-CBD’s effects on arterial stiffness follows its initial findings between July (https://ibn.fm/rUgQV) and September (https://ibn.fm/0tFtD) that hypertensive volunteers using the company’s processed CBD achieved a marked drop in blood pressure relative to generic CBD controls used as a placebo. 

DehydraTECH is an enabling technological solution that helps drug substances bypass the digestion-liver filtering cycle that may reduce their effectiveness. DehydraTECH’s platform works with the body to rapidly process drugs into the blood stream before potentially being filtered out by the liver’s enzyme-generating factory. 

Additional testing by Canada’s premier federally funded research organization, the National Research Council demonstrated DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity (“NME”) and that each drug tested remained stable and did not undergo change in chemical structure.  These findings are strongly supportive of accelerated regulatory filings such as the 505(b)(2) pathway permitted by the Food and Drug Administration and other international regulators, for more rapid market authorizations of prospective DehydraTECH-enabled, repurposed drugs (https://ibn.fm/YfxNf).

Lexaria will follow the HYPER-H21-2 study with two new hypertension studies, HYPER-H21-3 and HYPER-H21-4, a new six-week investigation in which multiple doses of DehydraTECH-CBD are expected to indicate further benefits for treating hypertension and arterial stiffness. 

Arterial stiffness naturally increases with age and is associated with increased mortality from diseases such as diabetes mellitus and kidney disorders, as well as the cardiovascular diseases that are the leading cause of death worldwide (https://ibn.fm/zizu8). Dr. Vernon V S Bonarjee, the head of the cardiology department at Norway’s Stavanger University Hospital, has noted that measuring arterial stiffness may serve as a predictive indicator for determining treatment for cardiovascular disease, even among otherwise asymptomatic individuals, demonstrating the condition’s significance (https://ibn.fm/siA0F).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

FingerMotion Inc. (FNGR) Continues To Drive Customer and Shareholder Value Through Innovative Technology

 

• FingerMotion currently targets over one billion users within the Chinese market
• The company is a crucial player within the telecommunications and insurtech markets, which are projected to post CAGRs of 5% and 48% from 2020-2025 and 2021-2028, respectively
• Progress is seen by the company’s move to form a collaborative alliance with Munich Re, through JiuGe, its wholly-owned subsidiary 

FingerMotion (OTCQX: FNGR) has defined itself as an evolving technology company that is constantly pushing boundaries in telecommunications, big data insights, and Rich Communication Services (“RCS”), among others. Its focus on the Chinese market has made it a force to be reckoned with, evidenced by its growing year-over-year revenue since its founding in 2016.

FNGR is driven by the desire to serve over one billion users within the Chinese market, with plans to expand its model to other markets. Under the leadership of Martin J. Shen, the company’s Chief Executive Officer (“CEO”), FNGR has made some incredible achievements as it works towards this ultimate goal. Its most recent milestone was forming a collaborative research alliance between Munich Re and Shanghai JiuGe Information Technology Co. Ltd., FNGR’s wholly-owned subsidiary (https://ibn.fm/QWPeR). 

This alliance will create value for end insurance customers and insurers through better technology, customer experience, and product offerings. It will utilize Sapientus, FNGR’s proprietary technology platform representing everything the company stands for and what it works towards. It is an advanced platform that pushes innovation to achieve previously unattainable insights by mining behavioral patterns and distinctive features, thereby extracting insights to drive better claim management decisions and increase underwriting efficacy.

Through proprietary platforms and technologies such as these, FNGR is slowly positioning itself to capitalize on two critical industries within the Chinese market- insurtech and telecom. Globally, the telecommunications market is expected to post a CAGR of 5% from 2020 to 2025, mainly driven by the growing adoption of 5G, coupled with the increased popularity of Internet of Things (“IoT”) applications (https://ibn.fm/qQ3kv). 

The Chinese telecom market is steadily growing, with the same trend reflecting on the insurtech industry. The latter was valued at $2.72 billion globally in 2020 and is expected to post a CAGR of 48.8% over the forecast period (2021 to 2028) (https://ibn.fm/hcgY4). FNGR plans to capitalize on this growth by laying down a solid foundation for growth and forging healthy partnerships with key players in the market.

So far, FNGR’s four primary offerings all leverage technology and innovation to improve the lifestyle of the public. But, more importantly, the company is further investing in its research and development to increase value for its shareholders. This indicates an enterprise that is as committed to the end consumer as it is to shareholders, an aspect that sets it apart from other players in the industry. This positions FNGR for inevitable growth as time progresses.

The impact of FNGR’s operations, strategic investments, technologies, and innovations are not just being felt within the Chinese market. Instead, it goes beyond China, making FNGR a key player in the global telecommunications and insurtech markets.

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – AmpliTech Group Inc. (NASDAQ: AMPG) Releases Acquisition Update, Anticipated Results

 AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art, signal-processing components for satellite and 5G communications networks, defense, space and other commercial applications, has completed the purchase of the assets and operations of Spectrum Semiconductor Materials Inc. Based in California, Spectrum is a rapidly growing global specialty distributor of semiconductor components. According to AMPG, the transaction should provide significant financial benefits to the company while also adding significant distribution reach. The announcement noted that Spectrum is on track to reach unaudited 2021 revenue $13 million unaudited revenue for 2021. The announcement also observed that Spectrum has an existing powerful distribution platform across the United States, Europe and Asia, which is ideal for AmpliTech’s new line of monolithic, microwave-integrated circuit (“MMIC”) chip designs. “Through the Spectrum acquisition we have substantially increased our revenue base with a well-managed, growing business known for high quality and excellent customer service,” said AmpliTech CEO Fawad Maqbool in the press release. “We expect the transaction will be immediately accretive to our top-and bottom-line financial performance. Spectrum also provides an ideal distribution platform to support the launch and commercialization of our MMIC chip solutions in core end markets of aerospace, defense, automotive and computing. We expect AmpliTech and Spectrum to play a key role in improving the speed and efficiency of 5G cellular networks and medium earth orbit and low earth orbit satellite communications systems around the world.”

To view the full press release, visit https://ibn.fm/sBT8P

About AmpliTech Group Inc.

AmpliTech designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G and IoT), space, defense and quantum computing markets as well as systems and component-design consulting services. AmpliTech has a 13-plus-year track record of developing high-performance custom solutions to meet the unique needs of some of the largest companies in the global industries that it serves. The company is proud of the unique skills, experience and dedication of its focused team, which enables AMPG to deliver superior solutions, faster time to market, competitive pricing and excellent customer satisfaction and repeat business. For more information about the company, please visit www.AmpliTechInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Flora Growth Corp. (NASDAQ: FLGC) Subsidiary Introduces New Dry Herb Consumer Products; Issues 2022 Revenue Guidance of $35-45 Million

 

• Flora Growth’s subsidiary, Vessel Brand, recently introduced new products for dry herb consumption and anticipates releasing additional products in 2022
• FLGC acquired Vessel in a transaction that closed in November
• Founded in 2018, Vessel is an industry leader in the cannabis consumer technology and accessories space
• Flora Growth also announced a 2022 revenue guidance of $35-45 million
• CEO Luis Merchan held a webinar on December 14 in which he highlighted the company’s 2021 operational performance, commented on the revenue guidance, and fielded questions

Flora Growth (NASDAQ: FLGC), an internationally focused company committed to delivering the most compelling customer experiences in the world through its collection of plant-based wellness and lifestyle brands, is building an ecosystem of products that will support market-leading innovation within categories that matter most to consumers exploring plant-based consumer goods.  

In fulfilling this objective as well as its operational tenet ‘lead by design’, Flora Growth recently announced its wholly owned subsidiary, Vessel Brand, had introduced a robust portfolio of new products for dry herb consumption (https://ibn.fm/PBhYJ).

The products include Helix, a patent-pending one-hitter made of pure brass for the cleanest inhalation and featuring a spiralized interior that doubles the length of the smoke path and filters as residue builds up; Eclipse Kit, an all-in-one dry herb smoking kit that includes a Drift case, a one-hitter, an inverted Carbon lighter, and a Basin stash jar; Ash, an exquisite and artful ashtray made with concrete and genuine walnut; and Grinder, a four-piece premium grinder made with precision-engineered aluminum and magnetic closures for easy use.

Vessel anticipates releasing other new dry herb accessories in 2022, including a small, lightweight grinder with wood inlay and textured grip.

“At Vessel, we work tirelessly to set new industry standards and look forward to continuing to deliver on that brand promise within the dry herb market,” said Vessel CEO and Founder James Choe. “These new products are just the beginning of what Vessel has in store for consumers across the globe.”

Acquired by Flora Growth in a transaction that closed in November, Vessel is an industry leader in cannabis consumer technology and accessories. The company strives to develop and offer products that elevate and personalize the consumption experience while delivering the best performance. Since its establishment in 2018, Vessel has witnessed rapid revenue growth by leveraging a go-to-market strategy for direct-to-consumer sales in the United States and global cannabis market. Its trailing 12-months revenue stood at $6.6 million, representing a 90% year-over-year increase (https://ibn.fm/G8TAm).

Vessel finds continued success by bringing to market innovative products and experiences that raise users’ expectations – the recently announced products, as well as those slated for launch in 2022, attest to this.

Meanwhile, revenues from Vessel as well as Flora’s other operating divisions, including wholesale cannabis revenues from its Cosechemos farm in Colombia, contributed to a 2022 revenue guidance of $35-45 million issued in a December 6 press release (https://ibn.fm/lQmeF). Flora subsequently held a webinar on December 14, in which CEO Luis Merchan updated shareholders and listeners on the company’s operational performance for 2021 to date, provided additional comments on the revenue guidance, and fielded questions.

As an internationally focused cannabis brand builder, Flora Growth has expanded its product offerings, assets, and brand portfolio through investments and acquisitions. So far, the brands and assets affiliated with the company can be found within the cannabis and hemp, food and beverage, skincare and cosmetics, lifestyle and apparel, ancillary and technology (under which Vessel falls), and nutraceuticals and wellness spaces.

Along with the design-led approach, which combines product design, user experience (“UX”), packaging, and social and environmental thoughtfulness to promote customer experience and engagement, Flora Growth focuses on building an experienced workforce as well as a community of customers.

For more information, visit the company’s website at www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html